You are here
Patient-reported sleep disruption as an independent prognostic factor for overall survival in metastatic colorectal cancer.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: Sleep disruption is a prevalent problem among cancer patients and survivors, but clinical correlates of poor sleep are understudied, especially in colorectal cancer. We recently showed that metastatic breast cancer patients with poor sleep efficiency have a shorter overall survival. The primary study objective is to clarify the relationship between subjective sleep disruption and survival in patients with metastatic colorectal cancer (MCC). Methods: 240 pts (63% male, mean age=59; SD=11.0) treated for MCC in 1st to 5th line of 5-fluorouracil based chemotherapy completed the QOL Questionnaire (EORTC QLQ-C30). We considered sleep to be disrupted if patients reported little to severe trouble sleeping (scores >0 ). Multivariate Cox models included age, gender, site of primary tumor, stage at diagnosis, number of metastatic sites, performance status and prior chemotherapy.
Abstracts by Ayhan Ulusakarya:
Detection of circulating tumor cells (CTCs) in central venous blood (CVB) versus peripheral venous blood (PVB) in patients with metastatic cancers.Meeting: 2015 ASCO Annual Meeting | Abstract No: e22039Category: Tumor Biology - Circulating Tumor Cells
Efficacy and safety of chronomodulated hepatic arterial infusion (chronoHAI) of irinotecan (I), oxaliplatin (0) and fluorouracil (F) as salvage treatment for patients (pts) with heavily pretreated liver-predominant metastatic colorectal cancer (MCC).Meeting: 2015 ASCO Annual Meeting | Abstract No: e14582
Subjective sleep problems and objective circadian disruption: Impact on outcomes in patients with metastatic colorectal cancer (MCC).Meeting: 2015 ASCO Annual Meeting | Abstract No: e14584